U-BIOPRED asthma cohort: Inflammatory markers and corticosteroid use

D. Gibeon, A. H. Wagener, X. Yang, A. R. Sousa, J. Corfield, D. E. Shaw, S. Fowler, L. J. Fleming, J. Riley, E. Jeyasingham, A. Rowe, K. Fichtner, G. Roberts, P. Bakke, F. Singer, T. Geiser, U. Frey, I. Horvarth, R. Polosa, K. Bønnelykke, N. Krug, R. Middelveld, S. E. Dahlen, B. Dahlen, G. Hedlin, S. Hashimoto, B. Nordlund, J. Musial, A. Woodcock, C. S. Murray, L. Pahus, P. Chanez, D. Myles, C. Compton, T. W. Higenbottam, P. Montuschi, J. Vestbo, L. Larsson, T. Sandstrom, H. Bisgaard, S. S. Wagers, P. H. Howarth, E. H. Bel, R. Djukanovic, P. J. Sterk, K. F. Chung (London, Nottingham, Manchester, Southampton, Horsham, United Kingdom; Amsterdam, Netherlands; Lund, Stockholm, Umeå, Sweden; Ingelheim am Rhein, Hannover, Germany; Bergen, Hvidovre, Norway; Bern, Switzerland; Budapest, Hungary; Catania, Rome, Italy; Copenhagen, Denmark; Krakow, Poland; Marseille, France; Maasmechelen, Belgium)

Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management

Session: Novel mechanisms for established drugs for asthma and COPD management
Session type: Oral Presentation
Number: 3029

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Gibeon, A. H. Wagener, X. Yang, A. R. Sousa, J. Corfield, D. E. Shaw, S. Fowler, L. J. Fleming, J. Riley, E. Jeyasingham, A. Rowe, K. Fichtner, G. Roberts, P. Bakke, F. Singer, T. Geiser, U. Frey, I. Horvarth, R. Polosa, K. Bønnelykke, N. Krug, R. Middelveld, S. E. Dahlen, B. Dahlen, G. Hedlin, S. Hashimoto, B. Nordlund, J. Musial, A. Woodcock, C. S. Murray, L. Pahus, P. Chanez, D. Myles, C. Compton, T. W. Higenbottam, P. Montuschi, J. Vestbo, L. Larsson, T. Sandstrom, H. Bisgaard, S. S. Wagers, P. H. Howarth, E. H. Bel, R. Djukanovic, P. J. Sterk, K. F. Chung (London, Nottingham, Manchester, Southampton, Horsham, United Kingdom; Amsterdam, Netherlands; Lund, Stockholm, Umeå, Sweden; Ingelheim am Rhein, Hannover, Germany; Bergen, Hvidovre, Norway; Bern, Switzerland; Budapest, Hungary; Catania, Rome, Italy; Copenhagen, Denmark; Krakow, Poland; Marseille, France; Maasmechelen, Belgium). U-BIOPRED asthma cohort: Inflammatory markers and corticosteroid use. Eur Respir J 2013; 42: Suppl. 57, 3029

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

Timothy Higenbottam - 21.10.2013 21:21
GREAT

You must Login to comment this presentation.

Related content which might interest you:

Evaluation of inflammatory markers IL-6 and MMP-9 in asthma Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms Year: 2015
Associated factors with persistent airflow limitation in asthma in U-BIOPRED Source: Annual Congress 2013 –Studies of asthma in man Year: 2013
A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013
Importance of concomitant local and systemic eosinophilia in uncontrolled asthma Source: International Congress 2014 – Biomarkers of asthma control Year: 2014
Predictors of exacerbations in asthma Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015
Cross-sectional analysis of the Belgian severe asthma registry (BSAR) Source: International Congress 2014 – Direct and indirect monitoring of comorbidities Year: 2014
Analysis of the inflammatory profile of children with controlled and uncontrolled severe asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Serum periostin in asthma: A potential biomarker for stratification in severe treatment-resistant asthma Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014
Sputum interleukin (IL)-13 as a biomarker for the evaluation of asthma control Source: International Congress 2014 – Airway biomarkers Year: 2014
Obesity influences inflammatory phenotype mainly in early onset severe asthmatics Source: International Congress 2014 – The assessment of comorbidities Year: 2014
Biomarkers for sputum eosinophilia in mild-moderate and severe adult-onset asthma patients Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014
Induced sputum lipid mediators in severe asthma Source: International Congress 2016 – Translational studies in lung disease Year: 2016
Phenotypic characteristics of asthma with small airways involvement Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma Year: 2016
Urinary LTE₄ may be associated with TH2-driven asthma: Initial data from the Pan-European U-BIOPRED IMI project Source: International Congress 2014 – Biomarkers of asthma control Year: 2014
Treating peripheral eosinophilia in asthma: Simple and effective Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013
Systemic cytokine signaling via IL-17 and its relation to clinical characteristics in children with asthma Source: International Congress 2015 – Paediatric asthma and allergy: lung function and biomarkers Year: 2015
Mapping out asthma in the out-patient clinic – The MAPOUT II study Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma Year: 2016
Implication of IL-18 in the chronic inflammation of severe refractory asthma Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014
Diagnostic accuracy of markers for detection of airway eosinophilia in asthma: A systematic review Source: International Congress 2014 – Airway biomarkers Year: 2014
ADEPT, airway disease endotyping for personalized treatment: Interim analysis of asthma patients Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013